HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
On May 18, 2017, Harvard Bioscience, Inc. (the Company) held its
2017 Annual Meeting of Stockholders (the Annual Meeting). At the
Annual Meeting, the Companys stockholders voted on the following
proposals: (i) the election of one Class II Director for a
three-year term, such term to continue until the annual meeting
of stockholders in 2020 and until such Directors successor is
duly elected and qualified or until his earlier resignation or
removal, (ii) the approval of an amendment to the Companys
Employee Stock Purchase Plan to increase the number of authorized
shares available for issuance by 300,000 shares of common stock,
(iii) the approval, by a non-binding advisory vote, of the
compensation of the Companys named executive officers, and (iv)
the approval, by a non-binding advisory vote, of the frequency
(one, two or three years) of the stockholder vote to approve the
compensation of the Companys named executive officers. Proposal 2
relating to the appointment of KPMG LLP as the Company
independent registered public accounting firm for the fiscal year
ending December 31, 2017 was withdrawn prior to the Annual
Meeting, as reported on the Companys Schedule 14A (Definitive
Additional Materials) filed with the Securities and Exchange
Commission on May 11, 2017. The voting results for the matters
submitted to a stockholder vote at the Annual Meeting are
reported below.
Proposal 1 – Election of Directors
John F. Kennedy was elected as Class II Directors for a
three-year term, such term to continue until the annual meeting
of stockholders in 2020 and until such Directors successor is
duly elected and qualified or until his earlier resignation or
removal. Due to the plurality election, votes could only be cast
in favor of or withheld from the nominee and thus votes against
were not applicable. The results of the election were as follows:
| Name | VotesFor | Votes Withheld | Broker Non-Votes | |||||||||
| John F. Kennedy | 17,855,456 | 6,557,217 | 6,596,297 | |||||||||
Proposal 2 Ratification of the Appointment of KPMG
LLP
The stockholder vote related to the appointment of KPMG LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017 was withdrawn prior to
the Annual Meeting and therefore no vote was recorded.
Proposal 3 Approval of an Amendment to the Employee
Stock Purchase Plan to Increase the Number of Authorized Shares
Available for Issuance by 300,000 Shares of Common
Stock
The amendment to the Companys Employee Stock Purchase Plan to
increase the number of authorized share available for issuance by
300,000 shares of common stock was approved as follows:
| Votes For | Votes Against | Votes Abstained | Broker Non-Votes | |||||||||||
| 19,587,905 | 4,466,959 | 357,809 | 6,596,297 | |||||||||||
Proposal 4 Approval, by Non-Binding Advisory Vote, of
the Compensation of the Named Executive Officers
The compensation of the Companys named executive officers was
approved, by a non-binding advisory vote, as follows:
| Votes For | Votes Against | Votes Abstained | Broker Non-Votes | |||||||||||
| 19,139,978 | 4,755,189 | 517,506 | 6,596,297 | |||||||||||
Proposal 5 Approval, by Non-Binding Advisory Vote, of
the Frequency (One, Two or Three Years) of the Stockholder Vote
on Compensation of the Named Executive Officers
A frequency of one year for the stockholder vote on the
compensation of the Companys named executive officers was
approved, by a non-binding advisory vote, as follows:
| Votes For 1 Year | Votes For 2 Years | Votes For 3 Years | Abstain | |||||||||||
| 20,427,984 | 81,183 | 2,768,716 | 1,134,790 | |||||||||||
About HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO)
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products. HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO) Recent Trading Information
HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO) closed its last trading session up +0.03 at 2.40 with 14,584 shares trading hands.